All In Biotech

Drug Trial Radar · NCT02621931

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Chronic Migraine

Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,130

Actual

Start

Mar 22, 2016

Primary completion

Apr 11, 2017

Study completion Apr 11, 2017

Sponsor

Sponsor type
Industry
First posted
Dec 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine

Conditions

  • Migraine

Interventions

  • FremanezumabDrug

    Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.

  • PlaceboDrug

    Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study DrugTime frame: Baseline (Days -28 to Day -1), Treatment (Days 1 - Week 12)
  2. Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 to Week 12

Locations

273 sites in 9 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 13628

    Birmingham, Alabama

  • Teva Investigational Site 13577

    Birmingham, Alabama

  • Teva Investigational Site 13577

    Birmingham, Alabama

  • Teva Investigational Site 13628

    Birmingham, Alabama

  • Teva Investigational Site 13606

    Phoenix, Arizona

  • Teva Investigational Site 13579

    Phoenix, Arizona

  • Teva Investigational Site 13579

    Phoenix, Arizona

  • Teva Investigational Site 13606

    Phoenix, Arizona

  • Teva Investigational Site 13602

    Little Rock, Arkansas

  • Teva Investigational Site 13602

    Little Rock, Arkansas

  • Teva Investigational Site 13568

    Encino, California

  • Teva Investigational Site 13568

    Encino, California

  • Teva Investigational Site 13546

    Fullerton, California

  • Teva Investigational Site 13546

    Fullerton, California

  • Teva Investigational Site 13540

    Long Beach, California

  • Teva Investigational Site 13540

    Long Beach, California

  • Teva Investigational Site 13632

    Redlands, California

  • Teva Investigational Site 13632

    Redlands, California

  • Teva Investigational Site 13571

    Redondo Beach, California

  • Teva Investigational Site 13571

    Redondo Beach, California

  • Teva Investigational Site 13573

    San Diego, California

  • Teva Investigational Site 13573

    San Diego, California

  • Teva Investigational Site 13538

    Santa Monica, California

  • Teva Investigational Site 13538

    Santa Monica, California

  • Teva Investigational Site 13594

    Santa Rosa, California

  • Teva Investigational Site 13594

    Santa Rosa, California

  • Teva Investigational Site 13595

    Walnut Creek, California

  • Teva Investigational Site 13595

    Walnut Creek, California

  • Teva Investigational Site 13629

    Aurora, Colorado

  • Teva Investigational Site 13629

    Aurora, Colorado

  • Teva Investigational Site 13557

    Boulder, Colorado

  • Teva Investigational Site 13557

    Boulder, Colorado

  • Teva Investigational Site 13593

    Colorado Springs, Colorado

  • Teva Investigational Site 13593

    Colorado Springs, Colorado

  • Teva Investigational Site 13633

    Denver, Colorado

  • Teva Investigational Site 13612

    Denver, Colorado

  • Teva Investigational Site 13612

    Denver, Colorado

  • Teva Investigational Site 13633

    Denver, Colorado

  • Teva Investigational Site 13631

    Englewood, Colorado

  • Teva Investigational Site 13631

    Englewood, Colorado

Showing 40 of 273 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.